Microbiota is important for immunology, hormonal and metabolic homeostasis in human and could influence on developing diabetes and obesity. Recent studies investigates microbiota by metagenomic sequencing, however, the composite of microbiota and its metabolic role has not been fully determined. Metagenomics and microbiome analysis could early diagnose metabolic disorders and suggest treatment options for metabolic diseases. In this study, the investigators investigate the composite of microbiota and deduct basic information for treatment models using metagenomic sequencing.
1. Cross-section study: normal/prediabetes/drug naïve type2 diabetes: compare microbiota using metagenomic sequencing among three groups. 2. Observational prospective study: metformin/sodium glucose co-transporter 2 (SGLT2) inhibitor/ezetimibe: compare microbiota using metagenomic sequencing before and after drug treatment.
Study Type
OBSERVATIONAL
Enrollment
150
newly diagnosed type 2 diabetes patients who start to metformin monotherapy
newly diagnosed type 2 diabetes patients who start to SGLT2 inhibitor monotherapy
newly diagnosed dyslipidemia patients who start to ezetimibe therapy
Yonsei University College of Medicine, Department of Internal Medicine, Division of Endocrinology, Severance Hospital, Diabetes center
Seoul, South Korea
RECRUITINGMetagenomic profile change
Stool metagenomic profile change in acute and chronic phase
Time frame: 10 days (acute effect)
Metagenomic profile change
Stool metagenomic profile change in acute and chronic phase
Time frame: 3 months (chronic effect)
blood glucose change
fasting blood glucose
Time frame: 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.